Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO 2022

Cancer patient symptom and physical function reporting by caregivers used as...

Dr Elad Neeman - Kaiser Permanente San Francisco Medical Center, San Francisco...

Cancer patient symptom and physical function reporting by caregivers used as predictors of adverse clinical outcomes ( Dr Elad Neeman - Kaiser Permanente San Francisco Medical Center, San Francisco, USA )

Rucaparib effective as maintenance therapy following first-line platinum-based...

Dr Bradley Monk - University of Arizona College, Tucson, USA

Rucaparib effective as maintenance therapy following first-line platinum-based chemo in ovarian cancer ( Dr Bradley Monk - University of Arizona College, Tucson, USA )

RAGNAR study evidences efficacy and safety of erdafitinib in patients with...

Dr Yohann Loriot - Institut Gustave Roussy, Villejuif, France

RAGNAR study evidences efficacy and safety of erdafitinib in patients with advanced FGFR+ malignancies ( Dr Yohann Loriot - Institut Gustave Roussy, Villejuif, France )

ASCO 2022: The latest in mRCC

Prof James Larkin, Dr Bernard Escudier, Prof Jens Bedke and Dr Toni Choueiri

ASCO 2022: The latest in mRCC ( Prof James Larkin, Dr Bernard Escudier, Prof Jens Bedke and Dr Toni Choueiri )

ASCO 2022: Testing and diagnostics in EGFR exon 20 insertion positive NSCLC

Prof Tony Mok - Chinese University of Hong Kong, Shatin, Hong Kong

ASCO 2022: Testing and diagnostics in EGFR exon 20 insertion positive NSCLC ( Prof Tony Mok - Chinese University of Hong Kong, Shatin, Hong Kong )

ASCO and WHO to collaborate on quality indicators for cancer facilities

Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland

ASCO and WHO to collaborate on quality indicators for cancer facilities ( Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland )

Lack of access to new cancer medicines in LMICs

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Lack of access to new cancer medicines in LMICs ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Adagrasib shows CNS penetration and encouraging intracranial activity for...

Dr Joshua Sabari - Perlmutter Cancer Center NYU Langone Health, New York, USA

Adagrasib shows CNS penetration and encouraging intracranial activity for KRASG12C-mutated NSCLC and active, untreated CNS metastases ( Dr Joshua Sabari - Perlmutter Cancer Center NYU Langone Health, New York, USA )

Spotlight on global cancer control at ASCO 2022

Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM

Spotlight on global cancer control at ASCO 2022 ( Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM )

ASCO 2022: Head and neck cancer highlights

Dr Mark Persky - NYU Langone’s Perlmutter Cancer Center, New York, USA

ASCO 2022: Head and neck cancer highlights ( Dr Mark Persky - NYU Langone’s Perlmutter Cancer Center, New York, USA )

UICC announces global coalition to increase access to essential cancer...

Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries ( Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control )

Comment: LUMINA results show that women with low levels of the Ki67 biomarker...

Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )

Biomarker guidance allows patients 55 or older with low-grade luminal A-type...

Dr Timothy J. Whelan - McMaster University, Ontario, Canada

Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )

Comment: Biomarker guidance allows patients 55 or older with low-grade luminal...

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Comment: Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Luminal A-type breast cancer patients with low levels of the Ki67 biomarker can...

Dr Timothy J. Whelan - McMaster University, Ontario, Canada

Luminal A-type breast cancer patients with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis...

Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio...

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor ( Dr Ruben A. Mesa - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

ASCO 2022: Panel discussion on bladder preservation

Dr Petros Grivas, Prof Rob Jones, Prof Phil Cornford and Prof Kurt Miller

ASCO 2022: Panel discussion on bladder preservation ( Dr Petros Grivas, Prof Rob Jones, Prof Phil Cornford and Prof Kurt Miller )

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for...

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cancer patients ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

ASCO 2022: Highlights and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2022: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Pembrolizumab demonstrates clinically meaningful improvement in distant...

Dr Georgina Long - The University of Sydney, Sydney, Australia

Pembrolizumab demonstrates clinically meaningful improvement in distant metastasis-free survival in patients with melanoma ( Dr Georgina Long - The University of Sydney, Sydney, Australia )

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer...

Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San...

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients ( Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

ASCO 2022: Breast cancer highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

ASCO 2022: Latest in prostate cancer, including PARP inhibitors

Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford

ASCO 2022: Latest in prostate cancer, including PARP inhibitors ( Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford )

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard...

Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma ( Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands )

Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA...

Dr Ajay Nooka - Winship Cancer Institute of Emory University, Georgia, USA

Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody ( Dr Ajay Nooka - Winship Cancer Institute of Emory University, Georgia, USA )

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper...

Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib ( Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain )

Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer...

Dr Pamela Kunz - Yale Cancer Center, New Haven, USA

Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer PFS than temozolomide alone ( Dr Pamela Kunz - Yale Cancer Center, New Haven, USA )

ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal...

Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain

ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour ( Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild...

Dr Chiara Cremolini - University of Pisa, Pisa, Italy

FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )

Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Dr Chiara Cremolini - University of Pisa, Pisa, Italy

Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )

Can we afford the cost of newly approved targeted therapeutics in the...

Dr Sana Al Sukhun - Al Hyatt Oncology Practice, Amman

Can we afford the cost of newly approved targeted therapeutics in the management of breast cancer globally? ( Dr Sana Al Sukhun - Al Hyatt Oncology Practice, Amman )

Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer

Dr Etienne Brain - Institut Curie, Paris, France

Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer ( Dr Etienne Brain - Institut Curie, Paris, France )

Dabrafenib plus trametinib significantly increases overall response rate in...

Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada

Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas ( Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada )

Comment: Dabrafenib plus trametinib significantly increases overall response...

Dr Melissa Hudson- St. Jude Children's Research Hospital, Memphis, USA

Comment: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas ( Dr Melissa Hudson- St. Jude Children's Research Hospital, Memphis, USA )

Dabrafenib plus trametinib significantly increases overall response rate in...

Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada

Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas ( Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada )

ASCO 2022: Latest developments in mHSPC and mCRPC

Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller

ASCO 2022: Latest developments in mHSPC and mCRPC ( Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller )

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity...

Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma ( Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA )

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03 ( Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA )

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2...

Dr Shanu Modi - Memorial Sloan Kettering Cancer Centre, Manhattan, USA

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression ( Dr Shanu Modi - Memorial Sloan Kettering Cancer Centre, Manhattan, USA )

Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides...

Dr Cathy Eng- Vanderbilt-Ingram Cancer Center, Nashville, USA

Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients ( Dr Cathy Eng- Vanderbilt-Ingram Cancer Center, Nashville, USA )

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic...

Dr Jane Lowe Meisel- Winship Cancer Institute of Emory University, Georgia, USA

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients ( Dr Jane Lowe Meisel- Winship Cancer Institute of Emory University, Georgia, USA )

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )

Comment: (RVd) ± , stem cell transplantation and R maintenance shows...

Dr Julie Gralow- Chief Medical Officer, ASCO

Comment: (RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients ( Dr Julie Gralow- Chief Medical Officer, ASCO )

Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose...

Dr Julie Gralow- Chief Medical Officer, ASCO

$Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients ( Dr Julie Gralow- Chief Medical Officer, ASCO )$

Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide...

Dr Martin McCabe- University of Manchester, Manchester, England

$Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients ( Dr Martin McCabe- University of Manchester, Manchester, England )$

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast...

Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients ( Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA )

High-dose ifosfamide standard of care for recurrent and primary refractory...

Dr Martin McCabe - University of Manchester, Manchester, England

$High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma ( Dr Martin McCabe - University of Manchester, Manchester, England )$

(RVd) ± , stem cell transplantation and R maintenance shows significance for...

Dr Paul Richardson- Dana Farber Cancer Institute, Boston, USA

(RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients ( Dr Paul Richardson- Dana Farber Cancer Institute, Boston, USA )

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3...

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )

Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides...

Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan

Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair...

Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer ( Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York )

Review: Best options in localised prostate cancer

Prof Eleni Efstathiou, Prof Oliver Sartor, Prof Kurt Miller and Prof Karim...

Review: Best options in localised prostate cancer ( Prof Eleni Efstathiou, Prof Oliver Sartor, Prof Kurt Miller and Prof Karim Fizazi )

Avasopasem produces significant improvement of severe oral mucositis in head...

Dr Carryn Anderson - University of Texas Medical Branch, Texas, USA

Avasopasem produces significant improvement of severe oral mucositis in head and neck patients ( Dr Carryn Anderson - University of Texas Medical Branch, Texas, USA )

Circulating tumour DNA analysis can help identify the need for adjuvant therapy...

Dr Jeanne Tie - The Peter MacCallum Cancer Centre, Melbourne, Australia

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer ( Dr Jeanne Tie - The Peter MacCallum Cancer Centre, Melbourne, Australia )

N-803-BCG combination shows promising results in BCG-unresponsive NMIBC

Dr Karim Chamie - UCLA School of Medicine, Los Angeles, USA

N-803-BCG combination shows promising results in BCG-unresponsive NMIBC ( Dr Karim Chamie - UCLA School of Medicine, Los Angeles, USA )

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle...

Dr Michael Wang - MD Anderson Cancer Center, Houston, USA

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cell lymphoma ( Dr Michael Wang - MD Anderson Cancer Center, Houston, USA )

Everolimus after surgery can improve outcomes in those with high-risk kidney...

Dr Christopher Ryan - OHSU Knight Cancer Institute, Portland, USA

Everolimus after surgery can improve outcomes in those with high-risk kidney cancer ( Dr Christopher Ryan - OHSU Knight Cancer Institute, Portland, USA )

Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone...

Dr Hope Rugo - University of California San Francisco, San Francisco, USA

Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone receptor HR+/HER2‐ advanced breast cancer patients ( Dr Hope Rugo - University of California San Francisco, San Francisco, USA )

Comment: Sacituzumab govitecan for HR+/HER2‐ advanced breast cancer

Dr Jane Lowe Meisel - Winship Cancer Institute of Emory University, Georgia, USA

Comment: Sacituzumab govitecan for HR+/HER2‐ advanced breast cancer ( Dr Jane Lowe Meisel - Winship Cancer Institute of Emory University, Georgia, USA )

Circulating tumour DNA analysis can help identify the need for adjuvant therapy...

Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer ( Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia )

UICC announces global coalition to increase access to essential cancer...

Dr Cary Adams - Chief Executive Officer, UICC

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries ( Dr Cary Adams - Chief Executive Officer, UICC )

ASCO and WHO to collaborate on quality indicators for cancer facilities

Dr André Ilbawi - Cancer Control Officer, WHO

ASCO and WHO to collaborate on quality indicators for cancer facilities ( Dr André Ilbawi - Cancer Control Officer, WHO )

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer

Dr Hope Rugo - University of California San Francisco, San Francisco, USA

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer ( Dr Hope Rugo - University of California San Francisco, San Francisco, USA )

Ramucirumab plus pembrolizumab improves OS in advanced NSCLC

Dr Roy Herbst - Yale Cancer Center, New Haven, USA

Ramucirumab plus pembrolizumab improves OS in advanced NSCLC ( Dr Roy Herbst - Yale Cancer Center, New Haven, USA )

Ibrutinib plus chemoimmunotherapy improved PFS for newly diagnosed MCL

Ibrutinib plus chemoimmunotherapy improved PFS for newly diagnosed MCL ( )

More from ecancer

An Error Occurred: Internal Server Error

Oops! An Error Occurred

The server returned a "500 Internal Server Error".

Something is broken. Please let us know what you were doing when this error occurred. We will fix it as soon as possible. Sorry for any inconvenience caused.